Publication date: 29/06/2017
iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Dr. Mohamed Ragab, M.D., has been appointed as Vice President of Corporate Development. He will be responsible for overseeing global strategic business opportunities that support the growth of iTeos both clinically and operationally.
Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at Bristol-Myers Squibb where he was involved in many major immune-oncology deals. Prior to that, he was Global Partnering Head, Oncology at Hoffman-La Roche (part of Roche Group) and before that he was the Life Cycle Leader, Anemia Oncology. He also held various positions at Pfizer, Ortho Biotech and Schering-Plough (now Merck & Co.). He holds a Master Degree in Radiation Oncology from Cairo University School of Medicine and holds a Bachelor of Medicine and Surgery from Cairo University School of Medicine.
Dr. Michel Detheux, Chief Executive Officer of iTeos, commented,
"We are delighted Dr. Ragab has joined iTeos and this is testament to the progress that we have made that we are now appointing someone of his caliber to our executive team. He has over 20 years of experience with strategic planning, business development and licensing deals specifically in oncology. His expertise will be invaluable as iTeos looks to expand its pipeline and explore the best strategic options for our proprietary drug programs."
Dr. Ragab, newly appointed Vice President of Corporate Development, said,
“I am excited to be joining iTeos during this period of rapid growth, particularly as the company is growing their presence in the US. iTeos has the science and technology to be at the forefront of cancer immunotherapies and I look forward to working with the team to advance the pipeline as rapidly as possible.”
iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic (“cold”) tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit www.iteostherapeutics.com.